巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Insmed

    INSM
    20.260
    0.690
    3.53%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Insmed - 延遲價格・最後更新於 20/05 12:15
    最高位
    20.260
    最低位
    19.350
    開市價
    --
    前收市價
    19.570
    成交量(千)
    30.16
    成交額(百萬)
    5.40
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    2,421.42
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    34.435 - 16.410
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Insmed
    證券代碼
    INSM.US
    所屬板塊
    Biotechnology
    公司業務
    Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
    發行量
    118372133
    公司總部
    700 US Highway 202/206
    公司網址
    https://www.insmed.com
    公司電郵
    investor.relations@insmed.com
    公司電話
    +1 908 977-9900
    暫無內容

    關於

    Insmed(INSM.US)所屬的行業板塊為Biotechnology。
    Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
    詳細公司背景可參考: https://www.insmed.com